Natera saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 66 to 71.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners typically have an RS Rating of at least 80 as they begin their largest price moves. See if Natera can continue to rebound and clear that threshold.
Natera is working on a consolidation with a 183.00 buy point. See if it can clear the breakout price in volume at least 40% higher than normal. It's a later-stage pattern, and investors should be aware that those are less likely to work.
The company posted 0% EPS growth in the latest quarterly report. Revenue increased 32%.
Natera earns the No. 20 rank among its peers in the Medical-Services industry group. GeneDx Holdings, Hims & Hers Health and InfuSystem Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Price Performance?
